Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer
Therapeutic Advances in Medical Oncology
Published online on March 14, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
The introduction of immune checkpoint inhibitors (ICIs) has represented a major therapeutic breakthrough for patients with mismatch repair-deficient (MMRd) endometrial cancer (EC). However, despite initial clinical success, a considerable subset of ...
The introduction of immune checkpoint inhibitors (ICIs) has represented a major therapeutic breakthrough for patients with mismatch repair-deficient (MMRd) endometrial cancer (EC). However, despite initial clinical success, a considerable subset of ...